Exact Sciences Corp. (NASDAQ:EXAS)’s share price shot up 3% on Thursday . The company traded as high as $20.85 and last traded at $20.74, with a volume of 1,362,035 shares traded. The stock had previously closed at $20.14.

A number of brokerages have recently weighed in on EXAS. Goldman Sachs Group Inc. upped their target price on Exact Sciences Corp. from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday. Roth Capital reaffirmed a “hold” rating and set a $15.00 target price (up from $11.00) on shares of Exact Sciences Corp. in a research report on Monday, August 1st. Zacks Investment Research raised Exact Sciences Corp. from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Friday, July 29th. Robert W. Baird reaffirmed an “outperform” rating and set a $18.00 target price on shares of Exact Sciences Corp. in a research report on Sunday, July 31st. Finally, BTIG Research reaffirmed a “buy” rating and set a $20.00 target price on shares of Exact Sciences Corp. in a research report on Sunday, July 31st. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $16.32.

The firm’s market capitalization is $2.05 billion. The stock’s 50-day moving average price is $15.91 and its 200 day moving average price is $9.16.

Exact Sciences Corp. (NASDAQ:EXAS) last issued its quarterly earnings data on Tuesday, July 26th. The company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.09. The business earned $21.20 million during the quarter, compared to the consensus estimate of $18.54 million. During the same quarter in the prior year, the business posted ($0.44) earnings per share. Exact Sciences Corp.’s quarterly revenue was up 161.7% compared to the same quarter last year. Analysts expect that Exact Sciences Corp. will post ($1.79) earnings per share for the current fiscal year.

In other news, COO Maneesh Arora sold 7,359 shares of the firm’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $14.82, for a total value of $109,060.38. Following the completion of the transaction, the chief operating officer now owns 538,736 shares in the company, valued at approximately $7,984,067.52. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Katherine S. Zanotti bought 3,380 shares of the stock in a transaction dated Wednesday, August 3rd. The stock was purchased at an average price of $17.93 per share, with a total value of $60,603.40. Following the purchase, the director now owns 105,927 shares in the company, valued at $1,899,271.11. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Exact Sciences Corp. stock. US Bancorp DE boosted its position in shares of Exact Sciences Corp. (NASDAQ:EXAS) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 229,594 shares of the company’s stock after buying an additional 5,109 shares during the period. US Bancorp DE owned 0.24% of Exact Sciences Corp. worth $2,119,000 at the end of the most recent quarter.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.